Skip to main
HOLX
HOLX logo

Hologic (HOLX) Stock Forecast & Price Target

Hologic (HOLX) Analyst Ratings

Based on 32 analyst ratings
Buy
Strong Buy 19%
Buy 25%
Hold 53%
Sell 3%
Strong Sell 0%

Bulls say

Hologic's positive outlook is supported by anticipated high-single digit growth in its Molecular Diagnostics segment, driven by increased utilization of its Panther system, which has seen a substantial expansion in its installed base. The company's overall revenue is projected to grow at a compound annual growth rate (CAGR) of approximately 4% from CY24E to CY26E, with potential for faster growth stemming from new product launches, margin improvements, and strategic acquisitions. Additionally, operating efficiencies are expected to yield annual margin expansion of about 30 basis points, contributing to an estimated earnings growth of over 10% through share repurchases and ongoing organic revenue growth.

Bears say

Hologic has revised its long-term revenue growth target from 5-7% to mid-single digits, indicating a significant slowdown that may see growth fall below this range in calendar year 2025. The company's bear case scenario anticipates revenue growth slowing to low-single digits, primarily due to declines in Diagnostics and Breast Health, coupled with concerns about deferred customer purchases awaiting new product launches, specifically Envision. Additionally, Hologic has adjusted its revenue growth estimates downward for FY25 and FY26 while maintaining earnings per share through buybacks and expense control, suggesting underlying weaknesses in operational performance.

Hologic (HOLX) has been analyzed by 32 analysts, with a consensus rating of Buy. 19% of analysts recommend a Strong Buy, 25% recommend Buy, 53% suggest Holding, 3% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hologic (HOLX) Forecast

Analysts have given Hologic (HOLX) a Buy based on their latest research and market trends.

According to 32 analysts, Hologic (HOLX) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.95, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.95, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hologic (HOLX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.